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Abstract
Background: Mutations in proteins involved in the glycosylphosphatidylinositol anchor biosynthesis and remodeling
pathway are associated with autosomal recessive forms of intellectual disability. Recently mutations in the
PGAP1 gene that codes for PGAP1, a protein localized in the endoplasmic reticulum responsible for the first
step of the remodeling of glycosylphosphatidylinositol was linked to a disorder characterized by psychomotor
retardation and facial dysmorphism. Whole exome sequencing (WES) was performed in siblings with severely
delayed myelination and psychomotor retardation. Mutations in PGAP1 were confirmed by Sanger sequencing
and RNA analysis. A literature search was performed to describe the emerging phenotype of PGAP1 related
disease.
Case presentation: WES resulted in the detection of two novel compound heterozygous mutations in PGAP1,
one base pair insertion leading to a frame shift c.334_335InsA (p.A112fs) and a splice site mutation leading to
exon skipping c.G1173C (p.L391L). A symptom not described in PGAP1 related disorder before but prominent
in the siblings were recurrent apnea especially during sleep that persisted at least until age 2 years. Sequential cerebral
MRI at age one and two year(s) respectively revealed frontal accentuated brain atrophy and significantly delayed
myelination.
Conclusion: We report siblings with two novel mutations in PGAP1. Other that the common symptoms related to
PGAP1 mutations including non-progressive psychomotor retardation, neonatal feeding problems, microcephaly and
brain atrophy these patients displayed severely delayed myelination and recurrent apneas thereby widing the clinical
spectrum associated with such mutations.
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Background
Genetic defects that affect the proper synthesis and re-
modeling of glycosylphosphatidylinositol (GPI) anchors
of cell surface proteins are a new group of autosomal
recessive disorders leading to intellectual disability. Of
the 26 genes that are involved in this process, mutations
in 13 have been described [1]. Other than intellectual
disability, congenital malformations affecting the central
nervous system (CNS) and other organs have been de-
scribed [2]. PGAP1 codes for PGAP1 (post-GPI attach-
ment to proteins 1) that is responsible for the first step
of the remodeling of glycosylphosphatidylinositol (GPI)-
anchors after they have been transferred to the proteins
by the GPI transaminase. PGAP1 is an endoplasmic
reticulum (ER)-associated GPI inositol-deacylase, which
cleaves the acyl chain from the inositol [3]. In 2014 the
first mutations, homozygous deletions c.589_591delCTT
(p.Leu197del), in PGAP1 were described in siblings from
Syria, floppy infants with developmental delay and se-
vere intellectual disability. Murakami et al. demonstrated
that the defect of PGAP1 did not lead to a decreased
expression level of GPI-anchored proteins on B lympho-
blastoid cells derived from one of the subjects, but to
GPI-anchors with an abnormal structure and altered
biochemical properties [2]. Since this original description
4 more families with mutations in this gene have been
described, all of them a result of whole-exome sequen-
cing (WES). Novarino et al. used WES to identify the
genetic base of the disease in 55 families with hereditary
spastic paraplegias [4]. They discovered a homozygous
splice site mutation (c.1952 + 1G > T) in PGAP1 in two
male first degree cousins with global developmental
delay, abnormal hand movements and increased deep
tendon reflexes suggesting a motor neuron disease.
More recently three further families have been de-
scribed. Firstly a 3 year old boy from the United States
with developmental delay and cortical visual impairment
who was found to be compound heterozygous for two
nonsense variants, c.1572 T >A (p.Tyr524*) and
c.1396C > T (p.Gln466*) in PGAP1 [5]. Secondly an 8 years
old boy from unrelated parents with muscular hypotonia,
feeding difficulties and developmental delay who was
shown to carry compound heterozygous c.274_276del
(p.Pro92del) and c.921_925del (p.Lys308Asnfs*25) muta-
tions in the PGAP1 gene [6]. Thirdly siblings of a consan-
guineous couple from North Turkey who are 1st
cousins, with muscular hypotonia, severe develop-
mental delay, microcephaly and retinal dystrophy
carrying a homozygote splice site mutation c.1090-
2A > G [7].
In this article we show the clinical symptoms and MRI
findings of two further patients with mutations in
PGAP1 thereby confirming and extending the phenotype
of PGAP1 related disease.
Case presentation
Clinical phenotype
Patients II-1 and II-2, dizygotic male twins and first chil-
dren of non-consanguineous Caucasian parents with an
unremarkable family history were born in the 30th week
of gestation due to maternal HELLP syndrome (Fig. 1).
Birth measures were normal for gestational age (II-1:
weight 1555 g, length 43 cm; II-2: weight 1410 g, length
41 cm) and no congenital anomalies were present. Both
children developed respiratory distress syndrome and
were treated with surfactant. At age 3 months recurrent
prolonged apnea occurred necessitating stimulation
mainly during sleep. Multiple EEGs did not show epilep-
tic activity during these episodes that persisted until age
2 years when they were last seen, despite anticonvulsive
therapy. Psychomotor development was severely delayed
in both children. At a corrected age of 12 months they
showed pendular eye movements with rotation nystag-
mus, no fixation or tracking. Generalized muscular
hypotonia was present with poor head control and pau-
city of spontaneous movements. Increased tendon
reflexes with positive Babinski sign were noted as well as
frequent myoclonus and tremor. At age 25 months II-1
was able to roll over and momentarily sit unsupported.
He was very alert and friendly, fixated and played
with objects. He could babble but did not speak. He
showed frequent myoclonus and a pronounced hyper-
excitability. Patient II-2 developed epilepsy during the
2nd year of life with atone seizures, desaturation, gaze
deviation and smacking movements that were suc-
cessfully treated with topiramate. At age 25 months
Fig. 1 Pedigree of reported family. Pedigree chart designer by
CeGaT GmbH [11]
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he showed less developmental progress than his
brother. He was able to roll on the side and grasp
objects but did not interact with the caretakers. Like
his brother he showed myoclonus and was hyperexcit-
able. At age 2 years both children presented with nor-
mal height and length. Head circumference was on
the 3rd centile in patient II-1 and below the 3rd cen-
tile in patient II-2.
Investigations for metabolic disorders including serum
levels for alkaline phosphatase, calcium, parathyroid hor-
mone and vitamin D, that have been found abnormal in
patients with other defects in the synthesis of GPI-
anchors, were repeatedly normal [8]. Nerve conduction
velocity as well as acoustic and visual evoked potentials
measured in patient II-2 were within the normal range.
Cerebral MRI at age one year showed frontal accentu-
ated brain atrophy and significantly delayed myelination
in T2-weighted images. On follow-up MRI at age two
years the amount of myelin was increased, however the
magnetization transfer (MT) saturation maps still re-
vealed a striking reduction of signal arising from myelin
compared to age matched controls. Brain atrophy was
also less pronounced in the follow up MRI (Fig. 2). MR
spectroscopy at age two years demonstrated a significant
reduction (>2 SD of mean control values [9]) of creatine
and choline concentration in both patients which may
point to a decreased amount of choline containing mye-
lin proteins and cell density a finding that has been
described in hypomyelinating conditions [10] (Fig. 3).
Molecular Analysis
The exome analyses yielded 65.96 million confidently
mapped reads with a mean coverage of X69. Following
alignment to the reference genome, 21,931 on-target
variants were noted. We removed variants which were
called less than X8, were off-target, synonymous (>4 bp
from exon/intron junction), MAF > 0.1 % at dbSNP138
and MAF > 1 % in the Hadassah in-house dbSNP. 98
variants survived this filtering process but only a single
couple resided in the same gene, PGAP1. These were chr2:
197781284InsT, NM_024989:c.334_335insA:p.A112fs and
Chr2: 197755552 C >G, NM_024989:c.G1173C:p.L391L,
affecting the donor splice site of exon 10.
Sanger sequencing showed that both patients were com-
pound heterozygous for the insertion, c.334_335InsA
(p.A112fs) which was shown to be inherited from the
mother, leading to a frame shift and the splice site muta-
tion, c.G1173C (p.L391L), in the PGAP1 gene which was
Fig. 2 Structural and quantitative MRI of patients and a healthy age matched control. a;b;e;f;i: T2-weighted images at the corrected age of
12 months (a, e) and 2 years (b, f, i) of patients II-1 (a, b) and patient II-2 (e, f) and control (i) showing brain atrophy and significant delayed
myelination in the patients. c;d;g;h;j;k: T1-weighted images and overlay of color coded MT saturation maps onto the corresponding T1-weighted
images of both patients (c, d, g, h) and an age matched control (j, k) at age 2 years. Yellow represents high signal intensity considered to arise
from properly myelinated WM. Both patients show widespread marked reductions of the myelinsensitive parameter MT saturation [12] when
compared to the age matched control thereby emphasizing the delayed myelination. For detailed information about MT saturation maps see
Additional file 1
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shown to be inherited from the father. cDNA analysis
from whole blood of patients and a healthy control re-
vealed on the one hand a transcript variant without exon
9 in patients as well as in healthy control. Additionally the
splice site mutation c.G1173C (p.L391L) leads to skipping
of exon 10 (Fig. 4). Thereby it is to suppose that the skip-
ping of the exon 10 leads to a truncated protein.
For detailed information about WES and Sanger
sequencing see Additional file 1.
Discussion
Including the two patients reported on in this article 10
patients from 6 different families carrying mutations in
the PGAP1 gene have been described so far [2, 4–7]. A
summary of the clinical and genetic findings is given in
Table 1. In none of the patients the disorder had a pro-
gressive course instead the patients showed a varying
degree of development. 8 patients were reported to have
had muscular hypotonia in the neonatal period leading
to feeding problems in 6. Tremor was observed in 3
patients, dyskinetic movements in 6. Only two patients
have been reported to walk independently, however the
majority of the patients were still young. Intellectual dis-
ability seems to be a constant feature but with varying
severity. Only one patient has been reported to be able
to speak. This patient was also the only normocephalic
patient while the others were microcephalic indicating
that he might be less severely affected. Epilepsy was
present in three out of ten patients and one additional
patient showed generalized slowing in the EEG without
clear epileptiform changes. Recurred apneas especially
during sleep, which were a very prominent symptom in
the patients described in this article, have not been
described in the other patients. Dysmorphic features
described in the patients include large ears, a flattened
nasal root [2], prominent forehead, large mouth, abnor-
mal teeth, high arched eyebrows, a short neck [5], up-
ward slanting palpebral fissures, deep-set eyes, large ear
lobes and prominent helices and antihelices, extra
mamelons of teeth and diminished enamel [6]. In
addition to the face malformations Williams et al.
described abnormal hand morphology in his patient.
Fig. 3 Structural MRI and MR-Spectroscopy. MR-Spectroscopy of parieto-occipital WM from both patients. Placements of volume of interest are
illustrated in T1- weighted images (left). Significant decreases (>2 SD of mean control value) of metabolite concentrations are indicated by black
arrows. The black asterix indicates marginally low concentration. (tNAA: sum of N-acetylaspartate and N-acetylaspartylglutamate, tCr: sum
of creatine and phosphocreatine, Cho: Choline, Ins: Inositol). For detailed information about MR-Spectroscopy see Additional file 1
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Metabolic analysis in the PGAP1 patients has overall
yielded unremarkable results. Hyperphosphatasia that
was described in other GPI-APs related disease (PIGV,
PIGO and PGAP2) due to recognition of mannose resi-
due in immature GPI and the consecutive cleavage of
the hydrophobic signal peptide from the proproteins by
GPI transamidase resulting in secretion of soluble alka-
line phosphatase [8]. But serum levels of alkaline phos-
phatase were normal in our patients and in the Pgap1
mouse model as well, suggesting elevated alkaline phos-
phatase is not part of PGAP1 disease. Imaging of the
brain was performed in 9 out of 10 patients (1 CT, 8
MRIs). Cerebral imaging revealed global brain atrophy
in 5/9 patients, defective myelination in 4/9, abnormal-
ities of the sylvian fissure in 2/9 and callosum agenesis
and vermis hypoplasia in one. One patient, the only pa-
tient that was able to speak, was reported to have a nor-
mal MRI at the age of 5 years again supporting the
milder course of the disease in this patient. The MRIs of
the siblings from North Turkey were also described to
be normal, but information of the patients’ age at inves-
tigation was not provided. Sequential MRIs, available in
the patient described by Williams et al. and the two
patients reported on in this article, demonstrate that the
amount of myelin detected on MRI is increasing indicat-
ing delayed myelination rather than defective myelin-
ation. However, the analysis of the MT saturation maps
shows that the amount of myelin is still decreased when
compared to age matched controls at the age of 2 years.
Single voxel proton MR spectroscopy also indicated a
defect in the myelin.
A knock-out mouse model of PGAP1 was described in
2007 with three different phenotypes that varied in se-
verity. Some mice showed a severe developmental defect
of the brain, similar to human otocephaly and others
only minor abnormalities like growth retardation or
male infertility. The mouse model therefore seems to re-
semble some of the features of PGAP1 related human
disease including the wide phenotypic variability.
Conclusion
The emerging clinical phenotype of PGAP1 related dis-
ease is rather unspecific. It includes non-progressive se-
vere psychomotor retardation and infrequent mild facial
dysmorphism. The probably most specific finding for
PGAP1 related disease, at least in our patients, was
Fig. 4 Sanger sequencing and cDNA analysis. a: Sanger sequencing of the PGAP1 gene in patient II-1 (upper row) and a control (lower row).
The arrows indicated the compound heterozygous mutations. b: Agarose gel electrophoresis of cDNA from blood of Patient II-1 on the right
and healthy control on the left. The red rectangles indicate the eluted bands using for subsequently sequencing. Letter a, b and c refer to the
corresponding sequences on the right
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Table 1 Clinical and genetic findings of PGAP1-disease
This Study Murakami et al. Bosch et al. Williams et al. Novarino et al. Granzow et al.
II-1 II-2 III-2 III-3 IV-3 IV-4 I-1 I-2













c.1572 T > A (p.Tyr524*) homozygous splice site mutation






c.1173G > C (p.Leu391Leu)
c.921_925del
(p.Lys308Asnfs*25)
c.1396C > T p.(Gln466*)
Gender M M F M M M M M M F
Agea 2 2 4 5/12 2 9/12 7 10/12 3 6 6/12 9/12 8 4
Pregnancy/Birth 30th weeks, maternal
HELLP syndrome
unremarkable planned CS, 38 weeks 39 weeks NA NA unremarkable
Facial dysmorphisms (+) (+) + + + + - - - -
Microcephaly + + + + - + NA NA + +
Intellectual disability + + IQ < 35 IQ < 35 IQ 49 + + - + +
Speech Babble Babble Babble NA 2 6/12 delayed NA NA - -
Motor developmental delay + + + + + + + - + +
Walking independently (years) - - 4 5/12 - 2 6/12 - NA NA NA -
Hypotonia + + + + + + NA NA + +
Neuropathy/Spasticity - - NA NA - - + + - +
Stereotypic/dyskinetic
movements
- - + + - + + + + -
Eating/Feeding Milk bottles Milk bottles Milk bottles Milk bottles - G-tube feeding NA NA - Failure to
thrive
Respiration Recurrent apneas Recurrent apneas - - - - NA NA + -
Ophthalmological findings - - - - CVI CVI - - Retinal dystrophy (ERG)
Seizures/EEG abnormalities −/− +/+ +/NA -/NA -/NA −/+ NA NA −/− −/−
Imaging Frontal accentuated brain
atrophy and significant
delayed myelination (MRI)

















CS caesarian section, CT computer tomography, CVI cortical visual impairment, EEG electroencephalogram, ERG electroretinogram, F female, IQ intelligence quotient, M male, MRI magnetic resonance imaging, NA
not available













severely delayed myelination. The fact that within only
one year since the original description 8 more patients
with genetic defects of PGAP1 have been described
might indicate that such defects are a more common
cause of intellectual disability and that the PGAP1 gene
should be included in gene panels for the analysis of
severe psychomotor retardation and delayed myelination.
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